Advertisement

Picture BioM Forum Translational Medicine 2018 Würzburg Germany 600x60px
Person › Details

Graham Mullis (Novacyt S.A. (Alternext: ALNOV))

Mullis, Graham (Novacyt 201409 CEO before Lab21 CEO)

 

Organisations Organisation Novacyt S.A. (Alternext: ALNOV)
  Group Novacyt (Group)
  Former/major organisation Lab21 Ltd.
  Group Novacyt (Group)
Products Product diagnostics (medical/biological)
  Product 2 cell analysis technology
     

Novacyt S.A.. (9/17/14). "Press Release: Novacyt Appoints Anthony Dyer as Finance Director". Paris & Cambridge.

Novacyt (ALTERNEXT: ALNOV), an international diagnostics manufacturer focused on cell-based diagnostics in the oncology and infectious disease markets, today announces that Anthony Dyer will become Finance Director, replacing Susan Lowther who is leaving the company.

Anthony has been employed part time by Lab21/Novacyt and is currently the Group Financial Controller. In addition to his role at Lab21/Novacyt, Anthony has also held the role of Senior Director of Finance at Galapagos N.V., during its recent sale of its service business to Charles River Laboratories for up to €134 million.

Graham Mullis, CEO of Novacyt, said: “We thank Susan for her support and contribution at Lab21 and more recently with the transaction with Novacyt SA. We are also delighted that Anthony has decided to join us full-time as Finance Director and with his experience at Galapagos we welcome him to the executive team. It is an exciting time within Novacyt as we position ourselves to increase sales from our existing products, move into new markets and we look forward to working with him to deliver Novacyt’s financial goals.”

- Ends -


About Novacyt Group

The Novacyt Group is a leader in the field of diagnostics with a growing portfolio of cancer and infectious disease products and services. Through its proprietary technology platform, NovaPrep®, and a strong international network provided by Lab21, its UK diagnostics subsidiary, it is able to provide an extensive range of oncology and infectious disease products globally. The Group has diversified sales from diagnostic reagents used in oncology, microbiology, haematology and serology markets, and its customers and partners include major corporates.

For more information please refer to the website: www.novacyt.com


Contacts:

For media and investor enquiries:
International Investor & Media
Tony Stephenson,
Exitus Communications,
+44 (0)7899 796655,
tony@exituscommunications.co.uk

French Investor & Media
Sophie Boulila / Emmanuel Huynh,
Newcap,
+33 (0)1 44 71 94 91,
novacyt@newcap.fr

NOVACYT
Graham Mullis
Chief Executive Officer
+44 7901 514121
Graham.mullis@novacyt.com

   
Record changed: 2018-09-26

Advertisement

Picture BioM Forum Translational Medicine 2018 Würzburg Germany 600x60px


More documents for Graham Mullis


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Banner Fairtec GmbH Solutions for Smarter Business Events Exhibitions 600x60px




» top